Efficacy of rituximab in refractory polymyositis.
We describe the effectiveness of rituximab, an anti-B lymphocyte monoclonal antibody, in a case of refractory polymyositis with interstitial pulmonary disease and anti-Jo-1 autoantibody (antisynthetase syndrome). Rituximab was well tolerated, and its efficacy in inflammatory myositis should be evaluated.
Department of Internal Medicine, Bicetre Hospital, Le Kremlin Bicetre, Paris, France.
Olivier
O
Lambotte
Rami
R
Kotb
Gwenola
G
Maigne
François-Xavier
FX
Blanc
Cécile
C
Goujard
Jean François
JF
Delfraissy
D000974:Antibodies, Antinuclear / Q000097:blood; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008875:Middle Aged; D017285:Polymyositis / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; C046750:Jo-1 antibody; D000069283:Rituximab